| Type 2 Diabetes Mellitus |
1 |
1 |
| GLP-1 Receptor Agonist |
0 |
0.97 |
| Receptors |
0 |
0.7 |
| Cardiovascular Risk Management |
0 |
0.43 |
| Heart Failure (HF) |
0 |
0.39 |
| Hypoglycemia |
0 |
0.32 |
| Weight Management |
0 |
0.27 |
| Cardiovascular disease |
0 |
0.26 |
| Renal Failure |
0 |
0.26 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.22 |
| HIV Infection |
0 |
0.22 |
| Obesity |
0 |
0.2 |
| NHS |
0 |
0.19 |
| Sulfonylureas |
0 |
0.19 |
| Patient Safety |
0 |
0.18 |
| Chronic Kidney Disease |
0 |
0.17 |
| Angina Pectoris |
0 |
0.16 |
| Acute Coronary Syndrome |
0 |
0.13 |
| Adverse Effects |
0 |
0.13 |
| Brachial |
0 |
0.13 |
| Metabolism |
0 |
0.13 |
| Nausea |
0 |
0.13 |
| Weight Loss |
0 |
0.13 |
| SGLT2 Inhibitor |
0 |
0.11 |
| Cerebrovascular Accident |
0 |
0.09 |
| Diarrhea |
0 |
0.09 |
| Hemoglobin A1c |
0 |
0.09 |
| Peripheral Artery Disease |
0 |
0.09 |
| Renal Disease |
0 |
0.09 |
| Europe |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hemoglobin |
0 |
0.06 |
| Hyperglycemia |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Kidney |
0 |
0.06 |
| Kidney, Ureter, and Bladder |
0 |
0.06 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.06 |
| Unstable Angina |
0 |
0.06 |
| Weight Gain |
0 |
0.06 |